Background: Hypothyroidism is associated with insulin resistance, dyslipidemia, and abnormal body composition. This study assessed changes in body composition and insulin resistance after thyroxine (T4) replacement in overt hypothyroidism. Methods: In this prospective longitudinal study carried out in a tertiary care center, adult nondiabetic patients with overt hypothyroidism were rendered euthyroid on T4. Anthropometry including skinfold thickness (SFT) at the triceps and subscapularis was recorded. Patients underwent testing for fasting plasma glucose, creatinine, serum insulin, T4, thyrotropin (TSH) and body composition analysis by dual-energy X-ray absorptiometry (DEXA) both before and at 2 months after restoration to the euthyroid state. Results: Twenty-seven patients (20 female and 7 male) aged 35.3 ± 11.0 years (min-max: 17-59 years) with overt hypothyroidism were recruited. Serum T4 at the time of recruitment was 48.9 ± 24.6 nmol/l (normal range = 64.4-142 nmol/l). All patients had TSH ≥50 µIU/l. Following treatment, there was a mean body weight reduction of 1.7 kg (p = 0.01). Waist circumference as well as triceps and subscapularis SFT decreased significantly (p < 0.001). There was no change in fat mass (FM), percentage of fat (%FM) or bone mineral content in any of the specified regions or in the body as a whole. In contrast, mean lean body mass (LBM) decreased significantly by 0.8 kg (p < 0.01) in the trunk and 1.3 kg (p < 0.01) in the whole body. Insulin resistance and level of glycemia were not affected by treatment with T4. Conclusion: LBM decreases significantly without affecting FM after correction of hypothyroidism. Insulin resistance was not influenced by T4 treatment.

Keywords:
Body composition, Hypothyroidism, Thyroxine, Lean body mass, Insulin resistance
1.
Chen WH, Chen YK, Lin CL, et al: Hashimoto's thyroiditis, risk of coronary heart disease, and L-thyroxine treatment: a nationwide cohort study. J Clin Endocrinol Metab 2015;100:109-114.
2.
Mayer O Jr, Simon J, Filipovsky J, et al: Hypothyroidism in coronary heart disease and its relation to the risk factors. Vasc Health Risk Manag 2006;2:499-406.
3.
Singh S, Duggal J, Molnar J, et al: Impact of subclinical thyroid disorders in coronary artery disease cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008;125:41-48.
4.
Stanicka S, Vondra K, Pelikanova T, et al: Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med 2005;43:715-720.
5.
Diekman T, Lansberg PJ, Kastelein JJ, et al: Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995;155:1490-1495.
6.
Biondi B, Cooper DS: Clinical significance of subclinical thyroid dysfunction. Endocr Rev 2007;29:76-131.
7.
Wolf M, Weigert A, Kreymann G: Body composition and energy expenditure in thyroidectomized patients during short-term hypothyroidism and thyrotropin-suppressive thyroxine therapy. Eur J Endocrinol 1996;134:168-173.
8.
Seppel T, Kosel A, Schlaghecke R: Bioelectrical impedance assessment of body composition in thyroid disease. Eur J Endocrinol 1997;136:493-498.
9.
Aguilar-Salinas CA, Gardun O-Garcia JJ, Alvirde-Garcia U, et al: TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol 2010;163:273-278.
10.
Feng Y, Hong X, Li Z, et al: Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. Obesity (Silver Spring) 2006;14:2089-2098.
11.
Ford ES: Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005;28:1769-1778.
12.
Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
13.
Sanchez A, Carretto H, Ulla MR, et al: Body Composition of patients with primary hypothyroidism evaluated by dual-energy X-ray absorptiometry and its changes after treatment with L-thyroxine. Endocrinologist 2004;14:321-328.
14.
Karmisholt J, Andersen S, Laurberg P: Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. J Clin Endocrinol Metab 2011;96:99-103.
15.
Cerit ET, Akturk M, Altinova AE, et al: Evaluation of body composition changes, epicardial adipose tissue, and serum omentin-1 levels in overt hypothyroidism. Endocrine 2015;49:196-203.
16.
Stangierski A, Ruchała M, Krauze T, et al: Treatment of severe thyroid function disorders and changes in body composition. Endokrynol Pol 2016, DOI: 10.5603/EP.a2016.0025.
17.
Razvi S, Pearce SH, Weaver JU: Does L-thyroxine reduce weight in people with subclinical hypothyroidism? Endocr Abstr 2006;12:P133.
18.
Wu TJ, Huang SM, Taylor RL, et al: Thyroxine effects on insulin like growth factor I levels, anthropometric measures, and body composition in patients after thyroidectomy. Ann Clin Lab Sci 2003;33:423-428.
19.
Going SB, Massett MP, Hall MC, et al: Detection of small changes in body composition by dual-energy X-ray absorptiometry. Am J Clin Nutr 1993;57:845-850.
20.
Prior BM, Cureton KJ, Modlesky CM, et al: In vivo validation of whole body composition estimates from dual-energy X-ray absorptiometry. J Appl Physiol 1997;83:623-630.
21.
Khaleeli AA, Gohil K, McPhail G, et al: Muscle morphology and metabolism in hypothyroid myopathy: effects of treatment. J Clin Pathol 1983;36:519-526.
22.
Uzzan B, Campos J, Cucherat M, et al: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81:4278-4289.
23.
Handisurya A, Pacini G, Tura A, et al: Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf) 2008;69:963-969.
24.
Kim MK, Kwon HS, Baek KH, et al: Effects of thyroid hormone on A1C and glycated albumin levels in nondiabetic subjects with overt hypothyroidism. Diabetes Care 2010;33:2546-2548.
25.
Anantarapu S, Vaikkakara S, Sachan A, et al: Effects of thyroid hormone replacement on glycated hemoglobin levels in non-diabetic subjects with overt hypothyroidism. Arch Endocrinol Metab 2015;59:495-500.
26.
Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, et al: Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 2016, DOI: 10.5603/EP.a2016.0030.
27.
Crunkhorn S, Patti ME: Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid 2008;18:157-165.
28.
Maratou E, Hadjidakis DJ, Kollias A, et al: Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160:785-790.
© 2016 European Thyroid Association Published by S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.